IN THE CLAIMS:

This listing of claims will replace all prior versions and listing of claims in the application. Listing of the claims:

Claims 1-15 (cancelled).

Claim 16 (currently amended): A quinazoline derivative of the Formula I according to claim 1 selected from :-

- 7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-5-tetrahydropyran-4-yloxyquinazoline,
- 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-{2-[(3RS,4SR)-3,4-methylenedioxypyrrolidin-1-yl]ethoxy}-5-tetrahydropyran-4-yloxyquinazoline,
- 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-[2-(4-prop-2-ynylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline,
- 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-[3-(4-prop-2-ynylpiperazin-1yl)propoxy]-5-tetrahydropyran-4-yloxyquinazoline,
- 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-(2-morpholinoethoxy)-5tetrahydropyran-4-yloxyquinazoline and
- 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-(3-morpholinopropoxy)-5-tetrahydropyran-4-yloxyquinazoline; or a pharmaceutically-acceptable acid-addition salt thereof.

Claim 17 (currently amended): A quinazoline derivative of the Formula I according to claim 1 selected from :-

- 7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-5-isopropoxyquinazoline,
- 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-5-isopropoxy-7-(2-piperazin-1-ylethoxy)quinazoline,
- 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-{2-[4-(2-hydroxyethyl)piperazin-1-yl]ethoxy}-5-isopropoxyquinazoline,

- 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-5-isopropoxy-7-(2-pyrrolidin-1-ylethoxy)quinazoline,
- 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-5-isopropoxy-7-(2-piperidinoethoxy)quinazoline,
- 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-5-isopropoxy-7-(2-morpholinoethoxy)quinazoline,
- 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-5-isopropoxy-7-(3-morpholinopropoxy)quinazoline,
- 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-5-isopropoxy-7-[2-(4-prop-2-ynylpiperazin-1-yl)ethoxy]quinazoline,
- 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-5-isopropoxy-7-[2-(4-methylpiperazin-1-yl)ethoxy]quinazoline and
- 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-
- 7-{2-[4-(2-dimethylaminoacetyl)piperazin-1-yl]ethoxy}-5-isopropoxyquinazoline; or a pharmaceutically-acceptable acid-addition salt thereof.

Claim 18 (cancelled).

Claim 19 (**currently amended**): A pharmaceutical composition which comprises a quinazoline derivative <u>according to any one of claims 16, 17 and 23-31 of the Formula I</u>, or a pharmaceutically-acceptable salt thereof, <u>according to claim 1</u> in association with a pharmaceutically-acceptable diluent or carrier.

Claims 20-22 (cancelled).

Claim 23 (**new**): A quinazoline derivative according to claim 16 which is: 7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-5-tetrahydropyran-4-yloxyquinazoline, or a pharmaceutically-acceptable acid-addition salt thereof.

ATTORNEY DOCKET NO.: 056291-5205

Application No.: 10/533,931

Page 4

Claim 24 (**new**): A quinazoline derivative according to claim 16 which is:

4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-{2-[(3RS,4SR)-

3,4-methylenedioxypyrrolidin-1-yl]ethoxy}-5-tetrahydropyran-4-yloxyquinazoline, or a pharmaceutically-acceptable acid-addition salt thereof

Claim 25 (new): A quinazoline derivative according to claim 16 which is:

4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-[2-(4-prop-2-ynylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline,

or a pharmaceutically-acceptable acid-addition salt thereof.

Claim 26 (**new**): A quinazoline derivative according to claim 16 which is:

yl)propoxy]-5-tetrahydropyran-4-yloxyquinazoline,

or a pharmaceutically-acceptable acid-addition salt thereof.

Claim 27 (new): A quinazoline derivative according to claim 17 which is:

7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-5-isopropoxyquinazoline,

or a pharmaceutically-acceptable acid-addition salt thereof.

Claim 28 (new): A quinazoline derivative according to claim 17 which is:

 $4\hbox{-}(5\hbox{-}chloro\hbox{-}2,3\hbox{-}methylenedioxypyrid-4-ylamino})\hbox{-}5\hbox{-}isopropoxy\hbox{-}7\hbox{-}(2\hbox{-}piperazin-4)\hbox{-}(3\hbox{-}chloro\hbox{-}2,3\hbox{-}methylenedioxypyrid-4-ylamino})$

1-ylethoxy)quinazoline,

or a pharmaceutically-acceptable acid-addition salt thereof.

Claim 29 (new): A quinazoline derivative according to claim 17 which is:

4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-7-{2-[4-(2-hydroxyethyl)piperazin-

1-yl]ethoxy}-5-isopropoxyquinazoline,

or a pharmaceutically-acceptable acid-addition salt thereof.

ATTORNEY DOCKET NO.: 056291-5205

Application No.: 10/533,931

Page 5

Claim 30 (**new**): A quinazoline derivative according to claim 17 which is: 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-5-isopropoxy-7-(2-pyrrolidin-

1-ylethoxy)quinazoline,

or a pharmaceutically-acceptable acid-addition salt thereof.

Claim 31 (new): A quinazoline derivative according to claim 17 which is:

 $\hbox{$4$-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-5-isopropoxy-}$

7-(2-piperidinoethoxy)quinazoline,

or a pharmaceutically-acceptable acid-addition salt thereof.